AstraZeneca Pharma India Limited (BOM: 506820)
India
· Delayed Price · Currency is INR 6,770.60
-362.50 (-5.08%)
At close: Nov 14, 2024
AstraZeneca Pharma India Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2019 - 2015 |
| Revenue | 14,845 | 12,955 | 10,030 | 8,056 | 8,136 | 8,318 | Upgrade
|
| Revenue Growth (YoY) | 30.10% | 29.17% | 24.50% | -0.98% | -2.19% | 14.21% | Upgrade
|
| Cost of Revenue | 8,244 | 6,008 | 3,660 | 3,169 | 3,010 | 3,116 | Upgrade
|
| Gross Profit | 6,601 | 6,947 | 6,370 | 4,887 | 5,125 | 5,202 | Upgrade
|
| Selling, General & Admin | 2,543 | 2,419 | 2,591 | 2,303 | 2,199 | 2,180 | Upgrade
|
| Other Operating Expenses | 2,429 | 2,610 | 2,111 | 1,679 | 1,539 | 1,795 | Upgrade
|
| Operating Expenses | 5,238 | 5,233 | 4,881 | 4,193 | 3,963 | 4,176 | Upgrade
|
| Operating Income | 1,363 | 1,714 | 1,489 | 693.6 | 1,163 | 1,026 | Upgrade
|
| Interest Expense | -10 | -12 | -6.3 | -9.5 | -10.9 | -11.4 | Upgrade
|
| Interest & Investment Income | 325.7 | 325.7 | 231.2 | 114.8 | 104.6 | 122.3 | Upgrade
|
| Currency Exchange Gain (Loss) | -5 | -5 | 2.8 | -1.3 | -5.4 | -4.4 | Upgrade
|
| Other Non Operating Income (Expenses) | 20.2 | 20.2 | 2.1 | 4.6 | 2.1 | 4.7 | Upgrade
|
| EBT Excluding Unusual Items | 1,694 | 2,043 | 1,718 | 802.2 | 1,253 | 1,137 | Upgrade
|
| Merger & Restructuring Charges | - | - | -211.3 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.3 | 0.3 | 24.9 | 28.2 | 21.7 | 2.9 | Upgrade
|
| Asset Writedown | -12.4 | -12.4 | - | - | -3.8 | - | Upgrade
|
| Other Unusual Items | -575.6 | 164.3 | -191 | - | - | - | Upgrade
|
| Pretax Income | 1,106 | 2,195 | 1,341 | 830.4 | 1,271 | 1,140 | Upgrade
|
| Income Tax Expense | 287.1 | 580.3 | 348.1 | 214.4 | 337.9 | 417.6 | Upgrade
|
| Net Income | 819.2 | 1,615 | 992.9 | 616 | 933 | 722.1 | Upgrade
|
| Net Income to Common | 819.2 | 1,615 | 992.9 | 616 | 933 | 722.1 | Upgrade
|
| Net Income Growth | -46.39% | 62.66% | 61.19% | -33.98% | 29.21% | 32.62% | Upgrade
|
| Shares Outstanding (Basic) | 25 | 25 | 25 | 25 | 25 | 25 | Upgrade
|
| Shares Outstanding (Diluted) | 25 | 25 | 25 | 25 | 25 | 25 | Upgrade
|
| Shares Change (YoY) | -0.03% | - | - | - | - | - | Upgrade
|
| EPS (Basic) | 32.77 | 64.60 | 39.72 | 24.64 | 37.32 | 28.88 | Upgrade
|
| EPS (Diluted) | 32.77 | 64.60 | 39.72 | 24.64 | 37.32 | 28.88 | Upgrade
|
| EPS Growth | -46.37% | 62.66% | 61.19% | -33.98% | 29.21% | 32.62% | Upgrade
|
| Free Cash Flow | 83.2 | 171.1 | 497.7 | 911.8 | 970.7 | 732 | Upgrade
|
| Free Cash Flow Per Share | 3.33 | 6.84 | 19.91 | 36.47 | 38.83 | 29.28 | Upgrade
|
| Dividend Per Share | - | 24.000 | 16.000 | 10.000 | 2.000 | 1.000 | Upgrade
|
| Dividend Growth | - | 50.00% | 60.00% | 400.00% | 100.00% | - | Upgrade
|
| Gross Margin | 44.46% | 53.63% | 63.51% | 60.66% | 63.00% | 62.53% | Upgrade
|
| Operating Margin | 9.18% | 13.23% | 14.84% | 8.61% | 14.29% | 12.33% | Upgrade
|
| Profit Margin | 5.52% | 12.47% | 9.90% | 7.65% | 11.47% | 8.68% | Upgrade
|
| Free Cash Flow Margin | 0.56% | 1.32% | 4.96% | 11.32% | 11.93% | 8.80% | Upgrade
|
| EBITDA | 1,538 | 1,832 | 1,613 | 826.7 | 1,326 | 1,180 | Upgrade
|
| EBITDA Margin | 10.36% | 14.14% | 16.09% | 10.26% | 16.30% | 14.18% | Upgrade
|
| D&A For EBITDA | 174.8 | 117.2 | 124.7 | 133.1 | 163.6 | 154.2 | Upgrade
|
| EBIT | 1,363 | 1,714 | 1,489 | 693.6 | 1,163 | 1,026 | Upgrade
|
| EBIT Margin | 9.18% | 13.23% | 14.84% | 8.61% | 14.29% | 12.33% | Upgrade
|
| Effective Tax Rate | 25.95% | 26.43% | 25.96% | 25.82% | 26.59% | 36.64% | Upgrade
|
| Revenue as Reported | 15,193 | 13,303 | 10,291 | 8,204 | 8,264 | 8,448 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.